Meanwhile, in the first phase 3 trial conducted in China (randomized, double-blind, and placebo-controlled trial), roxadustat was superior to placebo in increasing Hb levels in CKD patients with NDD-CKD. The gene discussed is GSTM1; the disease is chronic kidney disease.